Biodesix Announces New Commercial Organization and Executive Appointments
By: Colorado BioScience Association Date: 03/10/2020
New Structure Increases Customer Focus, Agility and Growth Opportunities
March 10, 2020 07:00 AM Eastern Daylight Time
BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc., a leading diagnostic company in lung cancer, today announced the realignment of their commercial executive team. Kieran O’Kane will be promoted to Chief Commercial Officer (CCO) and Bobbi Coffin, current Chief Marketing Officer, will become the Chief Growth Officer (CGO), effective immediately. The is intended to power the company’s growth strategy in 2020 and beyond.
“Biodesix is truly excited to welcome Kieran and Bobbi into their new roles. I am confident that these changes will accelerate our strategic growth plan, guiding us toward our vision to help improve the lives of patients with and at risk for lung cancer.”
Since joining Biodesix in 2018 as Head of Strategic Marketing and Corporate Development, Kieran O’Kane has played a leadership role in establishing Biodesix as a leader in the development of blood-based diagnostic solutions for lung cancer. During his time with Biodesix, he has led the successful acquisition of Integrated Diagnostics (Indi) and Oncimmune’s laboratory and incidental pulmonology nodule malignancy test, and has subsequently been instrumental in the commercial launch of the Nodify XL2TM and NodifyCDTTM tests.
“We are delighted to welcome Kieran to the executive team in the role of CCO during this key period in Biodesix’s growth,” commented Scott Hutton, CEO at Biodesix. “His passion and focus for putting the customer first, combined with successful track records in sales, marketing, corporate and product development, bring a distinct advantage to us in the marketplace. His extensive business experience of more than 20 years in diagnostics and biotech at companies like Biodesix, Nanostring, BMS and Roche positions Biodesix well for our next growth phase.”
To drive continued growth across all commercial aspects of its business and industry, Biodesix today also added a new Chief Growth Officer (CGO) position and named Bobbi Coffin as the inaugural CGO. Bobbi’s extensive diagnostic marketing background and seasoned experience of more than two decades in creating new pathways to growth while optimizing resources, maximizing the impact of investment, and monitoring future trends make her the ideal professional to lead this function. Bobbi joined Biodesix in 2015 from Exact Sciences where she was Vice President of Commercial Marketing and Strategy. Prior to that role, Bobbi held leadership positions at Precision Therapeutics and Cytyc/Hologic.
“Uncovering new opportunities with our customers, and developing and cultivating synergistic relationships with all levels of the healthcare system will be concentrated points of focus for us as we continue to grow the Biodesix brand and best position it to build on its legacy of success,” said Hutton. “Biodesix is truly excited to welcome Kieran and Bobbi into their new roles. I am confident that these changes will accelerate our strategic growth plan, guiding us toward our vision to help improve the lives of patients with and at risk for lung cancer.”
Biodesix is a lung cancer diagnostic solutions company covering the continuum of patient care from early risk classification of lung nodules through treatment guidance in late stage cancer. The Company develops blood-based diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer four approved, non-invasive tests for patients with lung cancer or suspicious lung nodules. The Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The Nodify XL2TM test and the Nodify CDTTM test evaluate the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges. For more information about Biodesix, please visit www.biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, Biodesix operates in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Jordona Jackson Smith for Biodesix